EUCTR2011-001459-35-IT进行中（未招募）不适用
MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY ON THE THERAPEUTIC EFFICACY AND SAFETY OF BECLOMETHASONE DIPROPIONATE SUSPENSION FOR INHALATION 800 micrograms TWICE DAILY VS PLACEBO ADDED TO ANTIBIOTIC THERAPY IN PATIENTS WITH ACUTE RHINOSINUSITIS - CLEAR
CHIESI0 个研究点开始时间: 2012年12月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects written informed consent obtained prior to any study-related procedures 2. Male and female out-patients aged between 18 and 65 years (inclusive). 3. History of previously diagnosed recurrent or chronic sinusitis that necessitated antibiotic therapy as judged by the investigator. 4. Clinical diagnosis of acute rhinosinusitis defined, according to the European Position Paper on Rhinosinusitis and Nasal Polyps 2012 (20), as the sudden onset of two or more relevant symptoms for <12 weels, one of which is: nasal blockage/obstruction/congestion OR nasal discharge (anterior/posterior nasal drip): AND the second one is: facial pain/pressure or/and reduction/loss of sense of smell. 5. A cooperative attitude and ability to be trained to use correctly the nebuliser with intranasal nose piece.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 164
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous sinus surgery; 2. Sinus lavage within the past 7 days; 3. Nasal polyposis or important nasal septum deviation; 4. Antibiotic use (by any route) in the past 30 days; 5. Recurrent moderate epistaxis; 6. Chronic bacterial sinusitis with evidence of failure of antimicrobial therapy; 7. Intranasal or systemic use of corticosteroids within the past 30 days; 8. Chronic use of corticosteroids or immunosuppressive agents; 9. Immunocompromised states; 10. Diagnosis of bronchial asthma or chronic obstructive pulmonary disease (COPD); 11. History of clinically significant cardiac (i.e. congestive heart failure or severe hypertension), renal (i.e. kidney failure), psychiatric (i.e. depression or mood disorders), hepatic (i.e. cholestatic jaundice or hepatic dysfunction), endocrine (i.e. hyperthyroidism or adrenal suppression) or pulmonary disease, or laboratory testing abnormalities, whose sequelae and/or treatments can interfere with the results or treatments of the present study; 12. History of psychiatric diseases likely to require treatment with antidepressant drugs during the study period or treatment with antidepressant drugs in the past 2 weeks; 13. Diagnosis of glaucoma or prostatic hypertrophy; 14. History of alcohol or drug abuse; 15. Allergy, sensitivity or intolerance to study drugs and/or study drugs formulations ingredients (e.g. corticosteroids ); 16. Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL or are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g. bilateral tubal ligation, hysterectomy) hormonal contraception (implantable, patch, oral) double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). A pregnancy test (urine) will be performed at screening in women of childbearing potential; 17. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study; 18. Participation in another trial in the past 12 weeks or who patients have been previously enrolled in this study.
研究者
相似试验
已完成
不适用
MULTICENTER, RANDOMIZED, DOUBLE-BLIND PARALLEL GROUPS STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF A SINGLE ORAL DOSAGE OF 400 MG OF OXIBENDAZOL AGAINST A SINGLE ORAL DOSAGE OF 500 MG OF MEBENDAZAOL IN THE TREATMENT OF INTESTINAL HELMIANTIASIS IN ADULTS-B839 Helminthiasis, unspecifiedHelminthiasis, unspecifiedB839PER-010-01SMITHKLINE BEECHAM INTERAMERICAN,
已完成
不适用
DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PARALLEL GROUPS AND CONTROLLED WITH PLACEBO STUDY, OF 15 DAYS OF DURATION, ON THE SAFETY OF THE DISLORATADINE SYRUP IN CHILDREN OVER 6 MONTHS AND LESS THAN 2 YEARS OF AGE-T784 Allergy, unspecifiedAllergy, unspecifiedT784PER-045-01SCHERING PLOUGH RESEARCH INSTITUTE,
未知
不适用
A MULTI-CENTRE, DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF TAFENOQUINE (SB-252263, WR238605) IN SUBJECTS WITH PLASMODIUM VIVAX MALARIA.PER-031-11GlaxoSmithKline,155
招募中
3 期
A clinical study to evaluate the efficacy, safety and tolerability of Fixed Dose Combination of Dapagliflozin 10 mg and metoprolol 50 mg XR versus metoprolol 50 mg XR in patients with heart failure.CTRI/2023/06/053569ERIS LIFESCIENCES LIMITED
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - CC-5013-CLL-001Relapsed or refractory CLL-B in patients previously treated with alkilating agents after failure of fludarabine treatmentMedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2006-004469-32-ITCELGENE CORPORATIO340